Phillip H Lam1,2, Poonam Bhyan1,2, Cherinne Arundel1,3, Daniel J Dooley1,2, Helen M Sheriff1,3, Selma F Mohammed4, Gregg C Fonarow5, Charity J Morgan6, Wilbert S Aronow7, Richard M Allman8, Finn Waagstein9, Ali Ahmed1,3. 1. Department of Medicine, Veterans Affairs Medical Center, Washington, D.C. 2. Department of Medicine, Georgetown University/MedStar Washington Hospital Center, Washington, D.C. 3. Department of Medicine, George Washington University, Washington, D.C. 4. MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, D.C. 5. Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles. 6. Department of Biostatistics, University of Alabama at Birmingham. 7. Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, New York. 8. Office of Geriatrics and Extended Care, Department of Veterans Affairs, Washington, D.C. 9. Department of Medicine, University of Gothenburg, Gothenburg, Sweden.
Abstract
BACKGROUND:Digoxin use has been associated with a lower risk of 30-day all-cause admission and readmission in patients with heart failure and reduced ejection fraction (HFrEF). HYPOTHESIS: Digoxin use will be associated with improved outcomes in patients with HFrEF receiving β-blockers. METHODS: Of the 3076 hospitalizedMedicare beneficiaries with HFrEF (EF <45%), 1046 received a discharge prescription for β-blockers, of which 634 were not ondigoxin. Of the 634, 204 received a new discharge prescription for digoxin. Propensity scores for digoxin use, estimated for each of the 634 patients, were used to assemble a matched cohort of 167 pairs of patients receiving and not receiving digoxin, balanced on 30 baseline characteristics. Matched patients (n = 334) had a mean age of 74 years and were 46% female and 30% African American. RESULTS: 30-day all-cause readmission occurred in 15% and 27% of those receiving and not receiving digoxin, respectively (hazard ratio [HR]: 0.51, 95% confidence interval [CI]: 0.31-0.83, P = 0.007). This beneficial association persisted during 4 years of follow-up (HR: 0.72, 95% CI: 0.57-0.92, P = 0.008). Digoxin use was also associated with a lower risk of the combined endpoint of all-cause readmission or all-cause mortality at 30 days (HR: 0.54, 95% CI: 0.34-0.86, P = 0.009) and at 4 years (HR: 0.76, 95% CI: 0.61-0.96, P = 0.020). CONCLUSIONS: In hospitalized patients with HFrEF receiving β-blockers, digoxin use was associated with a lower risk of 30-day all-cause readmission but not mortality, which persisted during longer follow-up.
RCT Entities:
BACKGROUND:Digoxin use has been associated with a lower risk of 30-day all-cause admission and readmission in patients with heart failure and reduced ejection fraction (HFrEF). HYPOTHESIS: Digoxin use will be associated with improved outcomes in patients with HFrEF receiving β-blockers. METHODS: Of the 3076 hospitalized Medicare beneficiaries with HFrEF (EF <45%), 1046 received a discharge prescription for β-blockers, of which 634 were not on digoxin. Of the 634, 204 received a new discharge prescription for digoxin. Propensity scores for digoxin use, estimated for each of the 634 patients, were used to assemble a matched cohort of 167 pairs of patients receiving and not receiving digoxin, balanced on 30 baseline characteristics. Matched patients (n = 334) had a mean age of 74 years and were 46% female and 30% African American. RESULTS: 30-day all-cause readmission occurred in 15% and 27% of those receiving and not receiving digoxin, respectively (hazard ratio [HR]: 0.51, 95% confidence interval [CI]: 0.31-0.83, P = 0.007). This beneficial association persisted during 4 years of follow-up (HR: 0.72, 95% CI: 0.57-0.92, P = 0.008). Digoxin use was also associated with a lower risk of the combined endpoint of all-cause readmission or all-cause mortality at 30 days (HR: 0.54, 95% CI: 0.34-0.86, P = 0.009) and at 4 years (HR: 0.76, 95% CI: 0.61-0.96, P = 0.020). CONCLUSIONS: In hospitalized patients with HFrEF receiving β-blockers, digoxin use was associated with a lower risk of 30-day all-cause readmission but not mortality, which persisted during longer follow-up.
Authors: Cynthia Feltner; Christine D Jones; Crystal W Cené; Zhi-Jie Zheng; Carla A Sueta; Emmanuel J L Coker-Schwimmer; Marina Arvanitis; Kathleen N Lohr; Jennifer C Middleton; Daniel E Jonas Journal: Ann Intern Med Date: 2014-06-03 Impact factor: 25.391
Authors: Phillip H Lam; Daniel J Dooley; Chakradhari Inampudi; Cherinne Arundel; Gregg C Fonarow; Javed Butler; Wen-Chih Wu; Marc R Blackman; Markus S Anker; Prakash Deedwania; Michel White; Sumanth D Prabhu; Charity J Morgan; Thomas E Love; Wilbert S Aronow; Richard M Allman; Ali Ahmed Journal: Int J Cardiol Date: 2016-11-04 Impact factor: 4.164
Authors: Ali Ahmed; Ahsan Husain; Thomas E Love; Giovanni Gambassi; Louis J Dell'Italia; Gary S Francis; Mihai Gheorghiade; Richard M Allman; Sreelatha Meleth; Robert C Bourge Journal: Eur Heart J Date: 2006-05-18 Impact factor: 29.983
Authors: Kanan Patel; Gregg C Fonarow; Dalane W Kitzman; Inmaculada B Aban; Thomas E Love; Richard M Allman; Mihai Gheorghiade; Ali Ahmed Journal: Eur J Heart Fail Date: 2012-07-03 Impact factor: 15.534
Authors: Mustafa I Ahmed; Michel White; O James Ekundayo; Thomas E Love; Inmaculada Aban; Bo Liu; Wilbert S Aronow; Ali Ahmed Journal: Eur Heart J Date: 2009-06-16 Impact factor: 29.983
Authors: Kumar Sanam; Vikas Bhatia; Navkaranbir S Bajaj; Saurabh Gaba; Charity J Morgan; Gregg C Fonarow; Javed Butler; Prakash Deedwania; Sumanth D Prabhu; Wen-Chih Wu; Michel White; Thomas E Love; Wilbert S Aronow; Ross D Fletcher; Richard M Allman; Ali Ahmed Journal: Am J Med Date: 2016-06-02 Impact factor: 4.965
Authors: D S Echt; P R Liebson; L B Mitchell; R W Peters; D Obias-Manno; A H Barker; D Arensberg; A Baker; L Friedman; H L Greene Journal: N Engl J Med Date: 1991-03-21 Impact factor: 91.245
Authors: M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman Journal: N Engl J Med Date: 1996-05-23 Impact factor: 91.245
Authors: Elena-Laura Antohi; Andrew P Ambrosy; Sean P Collins; Ali Ahmed; Vlad Anton Iliescu; Gad Cotter; Peter S Pang; Javed Butler; Ovidiu Chioncel Journal: Am J Ther Date: 2019 Mar/Apr Impact factor: 2.688
Authors: Phillip H Lam; Poonam Bhyan; Cherinne Arundel; Daniel J Dooley; Helen M Sheriff; Selma F Mohammed; Gregg C Fonarow; Charity J Morgan; Wilbert S Aronow; Richard M Allman; Finn Waagstein; Ali Ahmed Journal: Clin Cardiol Date: 2018-03-22 Impact factor: 2.882